{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:27:55Z","timestamp":1792751275006,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":8368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1017\/s1041610203008664","type":"journal-article","created":{"date-parts":[[2004,3,10]],"date-time":"2004-03-10T12:11:23Z","timestamp":1078920683000},"page":"51-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"S1","title":["The ABC of Alzheimer\u2019s Disease: Cognitive Changes and Their Management in Alzheimer\u2019s Disease and Related Dementias"],"prefix":"10.1016","volume":"14","author":[{"given":"Jody","family":"Corey-Bloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610203008664_bb0005","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson\u2019s disease: A community-based, prospective study","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0010","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","article-title":"Donepezil for cognitive impairment in Parkinson\u2019s disease: A randomised controlled study","volume":"72","author":"Aarsland","year":"2002","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0011-393X(98)85048-0","article-title":"Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer\u2019s type","volume":"59","author":"Agid","year":"1998","journal-title":"Current Therapeutic Research Clinical and Experimental"},{"key":"10.1017\/S1041610203008664_bb0020","first-page":"1172","article-title":"Butyrylcholinesterase (BuChE) alters the aggregation state of A\u03b2 amyloid","volume":"22","author":"Barber","year":"1996","journal-title":"Proceedings for Society for Neuroscience"},{"key":"10.1017\/S1041610203008664_bb0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1017\/S1041610203008664_bb0030","first-page":"35","article-title":"Typical clinical features","author":"Bouchard","year":"1996"},{"key":"10.1017\/S1041610203008664_bb0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer\u2019s disease\u2014Results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1017\/S1041610203008664_bb0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1098-3597(01)90047-X","article-title":"Dementia due to subcortical ischemic vascular disease","volume":"3","author":"Chui","year":"2001","journal-title":"Clinical Cornerstone"},{"key":"10.1017\/S1041610203008664_bb0045","first-page":"55","article-title":"A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer\u2019s disease","volume":"1","author":"Corey-Bloom","year":"1998","journal-title":"International Journal of Geriatric Psychopharmacology"},{"key":"10.1017\/S1041610203008664_bb0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0197-4580(00)00183-4","article-title":"Cognitive and behavioral heterogeneity in Alzheimer\u2019s disease: Seeking the neurobiological basis","volume":"21","author":"Cummings","year":"2000","journal-title":"Neurobiology and Aging"},{"issue":"Suppl. 3","key":"10.1017\/S1041610203008664_bb0055","first-page":"A468","article-title":"Rivastigmine provides behavioural benefits to Alzheimer\u2019s disease patients residing in a nursing home: Findings from a 26 week trial [Abstract S79.002]","volume":"54","author":"Cummings","year":"2000","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0060","unstructured":"Data on file, Novartis Pharma AG, Basel, Switzerland."},{"key":"10.1017\/S1041610203008664_bb0065","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0149-7634(94)90052-3","article-title":"Impaired brain microcirculation may trigger Alzheimer\u2019s disease","volume":"18","author":"De La Torre","year":"1994","journal-title":"Neuroscience Biobehavioral Review"},{"key":"10.1017\/S1041610203008664_bb0070","unstructured":"Doody, R., Houston, T., & Kershaw, P. (2001). The cognitive effects of galantamine are sustained for at least 24 months. 53rd Annual Meeting of American Academy of Neurology, 2001, Philadelphia, Pennsylvania, p. A456."},{"key":"10.1017\/S1041610203008664_bb0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0278-5846(01)00326-8","article-title":"Long-term effects of rivastigmine in moderately severe AD: Does early initiation of therapy offer sustained benefits?","volume":"26","author":"Doraiswamy","year":"2002","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02245293","article-title":"Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer\u2019s disease","volume":"108","author":"Ebmeier","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl. 2","key":"10.1017\/S1041610203008664_bb0085","first-page":"151","article-title":"Rivastigmine increases regional cerebral blood flow as assessed by magnetic resonance imaging (MRI) [Abstract P-066]","volume":"13","author":"Enz","year":"2001","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610203008664_bb0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1017\/S1041610297004699","article-title":"Vascular dementia: Challenge of clinical diagnosis","volume":"9","author":"Erkinjuntti","year":"1997","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610203008664_bb0095","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: A randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1017\/S1041610203008664_bb0100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000008243","article-title":"A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer\u2019s disease","volume":"44","author":"Farlow","year":"2000","journal-title":"European Neurology"},{"key":"10.1017\/S1041610203008664_bb0105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer\u2019s disease","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0110","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1046\/j.1471-4159.1995.64041888.x","article-title":"Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer\u2019s disease","volume":"64","author":"Flynn","year":"1995","journal-title":"Journal of Neurochemistry"},{"key":"10.1017\/S1041610203008664_bb0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"The \u201cmini mental state\u201d: A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatry Research"},{"key":"10.1017\/S1041610203008664_bb0120","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/WNL.33.8.961","article-title":"Alzheimer\u2019s disease: Focal cortical changes shown by positron emission tomography","volume":"33","author":"Foster","year":"1983","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0125","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1212\/WNL.52.8.1687","article-title":"Correlation between rates of brain atrophy and cognitive decline in Alzheimer\u2019s disease","volume":"52","author":"Fox","year":"1999","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000110771","article-title":"Assessment of functional changes in Alzheimer\u2019s disease","volume":"9","author":"Gauthier","year":"1990","journal-title":"Neuroepidemiology"},{"key":"10.1017\/S1041610203008664_bb0135","first-page":"263","article-title":"Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease","author":"Geula","year":"1994"},{"key":"10.1017\/S1041610203008664_bb0140","unstructured":"Giladi, N., Shabtai, H., Gurevich, T., Benbunan, B., Anca, M., et al. (in press). Rivastigmine (Exelon) for dementia in patients with Parkinson\u2019s disease. Acta Neurologica Scandinavica."},{"key":"10.1017\/S1041610203008664_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/0013-4694(90)90051-K","article-title":"Clinical utility of long latency \u201ccognitive\u201d event-related potentials (P300): The pros","volume":"76","author":"Goodin","year":"1990","journal-title":"Electromyography and Clinical Neurophysiology"},{"key":"10.1017\/S1041610203008664_bb0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-4943(82)90031-0","article-title":"A new rating scale for dementia syndromes","volume":"1","author":"Gottfries","year":"1982","journal-title":"Archives of Gerontology and Geriatrics"},{"key":"10.1017\/S1041610203008664_bb0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S104161020100758X","article-title":"Long-term use of rivastigmine in patients with dementia with Lewy bodies: An openlabel trial","volume":"13","author":"Grace","year":"2001","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610203008664_bb0160","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/01688638808402796","article-title":"Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type","volume":"10","author":"Grady","year":"1988","journal-title":"Journal of Clinical Neuropsychology"},{"key":"10.1017\/S1041610203008664_bb0165","unstructured":"Grossberg, G., Irwin, P., Spiegel, R., Mesenbrink, P., & Satlin, A. (in press). Rivastigmine in Alzheimer\u2019s disease: Efficacy over 2 years compared with historical controls. American Journal of Geriatric Psychiatry."},{"key":"10.1017\/S1041610203008664_bb0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1471-4159.2000.0740237.x","article-title":"Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer\u2019s disease","volume":"74","author":"Guan","year":"2000","journal-title":"Journal of Neurochemistry"},{"key":"10.1017\/S1041610203008664_bb0175","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ana.410420613","article-title":"Butyrylcholinesterase in the life cycle of amyloid plaques","volume":"42","author":"Guillozet","year":"1997","journal-title":"Annals of Neurology"},{"key":"10.1017\/S1041610203008664_bb0180","unstructured":"Guy, W. (Ed.). (1976). Clinical Global Impressions (CGI). In ECDEU assessment manual for psychopharmacology (pp. 218-222). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch."},{"key":"10.1017\/S1041610203008664_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0166-4328(88)90105-2","article-title":"Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis","volume":"27","author":"Hagan","year":"1988","journal-title":"Behavioral Brain Research"},{"key":"10.1017\/S1041610203008664_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.40.1.1","article-title":"The Lewy body variant of Alzheimer\u2019s disease: A clinical and pathologic entity","volume":"40","author":"Hansen","year":"1990","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0195","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1212\/WNL.46.3.656","article-title":"The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer\u2019s disease","volume":"46","author":"Heyman","year":"1996","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF03159971","article-title":"Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases","volume":"16","author":"Hoyer","year":"1992","journal-title":"Molecular Chemistry and Neuropathology"},{"key":"10.1017\/S1041610203008664_bb0205","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/0024-3205(94)00384-X","article-title":"Rodent models of memory dysfunction in Alzheimer\u2019s disease and normal aging: Moving beyond the cholinergic hypothesis","volume":"55","author":"Ingram","year":"1994","journal-title":"Life Sciences"},{"key":"10.1017\/S1041610203008664_bb0210","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","article-title":"Acetyl-cholinesterase accelerates assembly of amyloid-\u03b2-peptides into Alzheimer\u2019s fibrils: Possible role of the peripheral site of the enzyme","volume":"16","author":"Inestrosa","year":"1996","journal-title":"Neuron"},{"key":"10.1017\/S1041610203008664_bb0215","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJM198604103141506","article-title":"Alzheimer\u2019s disease","volume":"314","author":"Katzman","year":"1986","journal-title":"New England Journal of Medicine"},{"key":"10.1017\/S1041610203008664_bb0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1468-1331.2000.00046.x","article-title":"An efficacy and safety analysis of rivastigmine in Alzheimer\u2019s disease patients with concurrent vascular risk factors","volume":"7","author":"Kumar","year":"2000","journal-title":"European Journal of Neurology"},{"key":"10.1017\/S1041610203008664_bb0225","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/(SICI)1099-1166(200004)15:4<338::AID-GPS119>3.0.CO;2-U","article-title":"Donepezil for behavioural disorders associated with Lewy bodies; A case series","volume":"15","author":"Lanctot","year":"2000","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"Suppl. 1","key":"10.1017\/S1041610203008664_bb0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000051228","article-title":"Galantamine: Additional benefits to patients with Alzheimer\u2019s disease","volume":"11","author":"Lilienfeld","year":"2000","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1017\/S1041610203008664_bb0235","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0240","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1440-1614.1999.00650.x","article-title":"Dementia with Lewy bodies","volume":"33","author":"McKeith","year":"1999","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0245","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9","article-title":"Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial","volume":"15","author":"McKeith","year":"2000","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0250","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: A randomised double-blind, placebo-controlled international study","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet"},{"key":"10.1017\/S1041610203008664_bb0255","first-page":"32","article-title":"Oral tetrahydroaminoacridine treatment of Alzheimer\u2019s disease evaluated clinically and by regional cerebral blood flow and EEG","volume":"4","author":"Minthon","year":"1993","journal-title":"Dementia"},{"key":"10.1017\/S1041610203008664_bb0260","first-page":"1","article-title":"ADAS-Cog: What, why and how?","volume":"3","author":"Mohs","year":"1997","journal-title":"Alzheimer Insights"},{"key":"10.1017\/S1041610203008664_bb0265","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0270","first-page":"S7","article-title":"Measuring response to treatment in Alzheimer\u2019s disease: What constitutes meaningful change?","volume":"1","author":"Mohs","year":"1998","journal-title":"International Journal of Geriatric Psychopharmacology"},{"key":"10.1017\/S1041610203008664_bb0275","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1041610296002761","article-title":"The utility of clinical trial batteries in the measurement of Alzheimer\u2019s and Huntington\u2019s dementia","volume":"3","author":"Mohr","year":"1996","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610203008664_bb0280","doi-asserted-by":"crossref","unstructured":"Moretti, R., Torre, P., Antonello, R. M., & Cazzato, G. (in press). Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up. European Journal of Neurology, 8, 361-362.","DOI":"10.1046\/j.1468-1331.2001.00224.x"},{"key":"10.1017\/S1041610203008664_bb0285","unstructured":"Moretti, R., Torre, P., Antonello, R. M., & Cazzato, G. (in press). Rivastigmine in subcortical vascular dementia: A randomized, controlled, open 22-month study. Journal of Neurological Science."},{"key":"10.1017\/S1041610203008664_bb0290","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","article-title":"Correlation between elevated levels of amyloid betapeptide in the brain and cognitive decline","volume":"283","author":"N\u00e4slund","year":"2000","journal-title":"Journal of the American Medical Association"},{"key":"10.1017\/S1041610203008664_bb0295","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/gps.930100306","article-title":"The Cognitive Drug Research computerized assessment system in the evaluation of early dementia\u2014Is it speed of the essence?","volume":"10","author":"Nicholl","year":"1995","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"Suppl. 2","key":"10.1017\/S1041610203008664_bb0300","first-page":"S147","article-title":"Improved cortical glucose metabolism in Alzheimer\u2019s disease (AD) patients treated with rivastigmine for one year [Abstract P0409]","volume":"187","author":"Nordberg","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"issue":"Suppl. 1","key":"10.1017\/S1041610203008664_bb0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1017\/S1041610297004778","article-title":"Alzheimer\u2019s Disease Assessment Scale-cognitive in clinical practice","volume":"9","author":"Pena-Casanova","year":"1997","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610203008664_bb0310","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.2.6150.1457","article-title":"Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia","volume":"2","author":"Perry","year":"1978","journal-title":"British Medical Journal"},{"key":"10.1017\/S1041610203008664_bb0315","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/jnnp.48.5.413","article-title":"Cholinergic correlates of cognitive impairment in Parkinson\u2019s disease: Comparisons with Alzheimer\u2019s disease","volume":"48","author":"Perry","year":"1985","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0320","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0022-510X(90)90236-G","article-title":"Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly","volume":"95","author":"Perry","year":"1990","journal-title":"Journal of Neurological Science"},{"key":"10.1017\/S1041610203008664_bb0325","first-page":"397","article-title":"Altered consciousness and transmitter signalling in Lewy body dementia","author":"Perry","year":"1996"},{"key":"10.1017\/S1041610203008664_bb0330","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00001756-199612200-00021","article-title":"Tacrine overcompensates for the decreased blood flow induced by basal forebrain lesion in the rat","volume":"8","author":"Peruzzi","year":"1996","journal-title":"Neuroreport"},{"key":"10.1017\/S1041610203008664_bb0335","unstructured":"Pratt, R. D., Perdomo, C. A., & the 307 Study Group. (2002). Donepezil improves cognition in patients with vascular dementia: Results from study 307, a 24-week randomized, double-blind, placebo-controlled trial [poster], 7th International Geneva\/Spring-field Symposium on Advances in Alzheimer Therapy, April 3-6, 2002, Geneva, Switzerland, P73A."},{"key":"10.1017\/S1041610203008664_bb0340","unstructured":"Pratt, R. D., Perdomo, C. A., & the 308 Study Group. (2002). Cognitive and global benefits of donepezil in vascular dementia: Results from Study 308, a 24-week, randomized, double-blind, placebo-controlled trial [poster], 7th International Geneva\/Spring-field Symposium on Advances in Alzheimer Therapy, April 3-6, 2002, Geneva, Switzerland, P72A."},{"key":"10.1017\/S1041610203008664_bb0345","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0350","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","article-title":"Rivastigmine in the treatment of parkin-sonian psychosis and cognitive impairment: Preliminary findings from an open trial","volume":"16","author":"Reading","year":"2001","journal-title":"Movement Disorders"},{"key":"10.1017\/S1041610203008664_bb0355","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","article-title":"The Global Deterioration Scale for assessment of primary degenerative dementia","volume":"139","author":"Reisberg","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0360","first-page":"8","article-title":"Clinical global measure of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines","volume":"11","author":"Reisberg","year":"1997","journal-title":"Alzheimer Diseases and Associated Disorders"},{"key":"10.1017\/S1041610203008664_bb0365","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0370","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study","volume":"158","author":"Rogers","year":"1998","journal-title":"Archives of Internal Medicine"},{"key":"10.1017\/S1041610203008664_bb0375","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-977X(97)00079-5","article-title":"Longterm efficacy and safety of donepezil in the treatment of Alzheimer\u2019s disease: An interim analysis of the results of a United States multicentre open-label extension study","volume":"8","author":"Rogers","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1017\/S1041610203008664_bb0380","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer\u2019s disease: Final analysis of a US multicentre open-label study","volume":"10","author":"Rogers","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1017\/S1041610203008664_bb0385","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0390","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: An international randomised controlled trial","volume":"318","author":"R\u00f6sler","year":"1999","journal-title":"British Medical Journal"},{"key":"10.1017\/S1041610203008664_bb0395","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0006-8993(83)90017-3","article-title":"Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer\u2019s disease","volume":"289","author":"Rylett","year":"1983","journal-title":"Brain Research"},{"issue":"Suppl. 1","key":"10.1017\/S1041610203008664_bb0400","first-page":"S53","article-title":"Long-term efficacy, safety and tolerability of donepezil: A 2-year open label study [Abstract P-0120]","volume":"187","author":"Sakka","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1017\/S1041610203008664_bb0405","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0006-8993(90)91561-T","article-title":"Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer\u2019s disease and multi-infarct dementia","volume":"521","author":"Sakurada","year":"1990","journal-title":"Brain Research"},{"key":"10.1017\/S1041610203008664_bb0410","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-0404.2000.00310.x","article-title":"Galantamine is an allosterically potentiating ligand of the human alpha4\/beta2 nAChR","volume":"176","author":"Samochocki","year":"2000","journal-title":"Acta Neurologica Scandinavica Supplement"},{"issue":"Suppl. 1","key":"10.1017\/S1041610203008664_bb0415","first-page":"S26","article-title":"Systematic review of the efficacy of rivastigmine for patients with Alzheimer\u2019s disease","volume":"1","author":"Schneider","year":"1998","journal-title":"International Journal of Geriatric Psychopharmacology"},{"key":"10.1017\/S1041610203008664_bb0420","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/jcbfm.1993.89","article-title":"Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats","volume":"13","author":"Scremin","year":"1993","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1017\/S1041610203008664_bb0425","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S1041610298005341","article-title":"Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients","volume":"10","author":"Shea","year":"1998","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610203008664_bb0430","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gps.930060208","article-title":"The cognitive drug research computerized assessment system for demented patients: A validation study","volume":"6","author":"Simpson","year":"1991","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0435","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00325481.1991.11701056","article-title":"Alzheimer\u2019s disease. Recognizing and treating a frustrating condition","volume":"90","author":"Skelton","year":"1991","journal-title":"Postgraduate Medicine"},{"key":"10.1017\/S1041610203008664_bb0440","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/1099-1166(200012)15:12<1147::AID-GPS262>3.0.CO;2-L","article-title":"Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil","volume":"15","author":"Skjerve","year":"2000","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0445","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1176\/ajp.151.3.390","article-title":"A longitudinal study of Alzheimer\u2019s disease: Measurement, rate, and predictors of cognitive deterioration","volume":"151","author":"Stern","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610203008664_bb0450","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0455","first-page":"1590","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting","volume":"49","author":"Tariot","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610203008664_bb0460","first-page":"51","article-title":"Dementia of the Alzheimer type: Defining a disease","author":"Terry","year":"1994"},{"key":"10.1017\/S1041610203008664_bb0465","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00002826-200101000-00007","article-title":"Donepezil, rivastigmine, and vitamin E in Alzheimer disease: A combined P300 event-related potentials\/neuropsychologic evaluation over 6 months","volume":"24","author":"Thomas","year":"2001","journal-title":"Clinical Neuropharmacology"},{"key":"10.1017\/S1041610203008664_bb0470","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1212\/WNL.54.2.407","article-title":"Cholinergic dysfunction in diseases with Lewy bodies","volume":"2554","author":"Tiraboschi","year":"2000","journal-title":"Neurology"},{"key":"10.1017\/S1041610203008664_bb0475","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/BF01271206","article-title":"Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia","volume":"103","author":"Tohgi","year":"1996","journal-title":"Journal of Neural Transmission"},{"key":"10.1017\/S1041610203008664_bb0480","first-page":"1408","article-title":"Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: A positron emission tomography study in unanesthetized monkeys","volume":"281","author":"Tsukada","year":"1997","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1017\/S1041610203008664_bb0485","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0166-4328(89)80081-6","article-title":"Selective fimbra lesions impair acquisition of working and reference memory of rats in a complex spatial discrimination task","volume":"32","author":"Van der Staay","year":"1989","journal-title":"Behavior Brain Research"},{"key":"10.1017\/S1041610203008664_bb0490","unstructured":"Van Laar, T., de Vries, J. J., Nakhosteen, A., & Leenders, K. L. (2001). Rivastigmine is effective and safe as anti-psychotic treatment in patients with Parkinson\u2019s disease. XIV International Congress on Parkinson\u2019s disease (CPD), Helsinki, Finland, 27 July-1 August."},{"key":"10.1017\/S1041610203008664_bb0495","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001756-200201210-00020","article-title":"Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer\u2019s disease","volume":"13","author":"Venneri","year":"2002","journal-title":"Neuroreport"},{"key":"10.1017\/S1041610203008664_bb0500","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/089198879100400406","article-title":"A new assessment tool for neuropsychophar-macologic research: The Computerized Neuropsychological Test Battery","volume":"4","author":"Veroff","year":"1991","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1017\/S1041610203008664_bb0505","first-page":"189","article-title":"Daily living activities in the assessment of dementia","author":"Weintraub","year":"1982"},{"key":"10.1017\/S1041610203008664_bb0510","first-page":"307","article-title":"Selectivity of cholinesterase inhibition","volume":"12","author":"Weinstock","year":"1999","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1017\/S1041610203008664_bb0515","first-page":"143","article-title":"Attention measurement differentiates drug effects in Alzheimer\u2019s disease [Abstract P-049]","volume":"73","author":"Wesnes","year":"2001","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610203008664_bb0520","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000048651","article-title":"Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study using the cognitive drug research computerised assessment system","volume":"13","author":"Wesnes","year":"2002","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"Suppl. 3","key":"10.1017\/S1041610203008664_bb0525","first-page":"56","article-title":"Quality of life assessment in dementia drug development","volume":"11","author":"Whitehouse","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1017\/S1041610203008664_bb0530","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.410100203","article-title":"Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis","volume":"10","author":"Whitehouse","year":"1981","journal-title":"Annals of Neurology"},{"key":"10.1017\/S1041610203008664_bb0535","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0022-510X(82)90045-4","article-title":"Alzheimer\u2019s disease. Correlation of cortical choline acetyl-transferase activity with the severity of dementia and histological abnormalities","volume":"57","author":"Wilcock","year":"1982","journal-title":"Journal of Neurological Sciences."},{"key":"10.1017\/S1041610203008664_bb0540","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: Multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"British Medical Journal"},{"key":"10.1017\/S1041610203008664_bb0545","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: A randomized, double-blind, dose-comparison in patients with Alzheimer\u2019s disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"Suppl. 2","key":"10.1017\/S1041610203008664_bb0550","first-page":"232","article-title":"Reminyl (Galantamine) produces significant improvements in symptoms in patients with \u2018advanced moderate\u2019 Alzheimer\u2019s disease [Abstract P-228]","volume":"13","author":"Wilkinson","year":"2001","journal-title":"International Psychogeriatrics"},{"issue":"Suppl. 3","key":"10.1017\/S1041610203008664_bb0555","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224044326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224044326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610203008664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T06:35:24Z","timestamp":1735799724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224044326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":111,"alternative-id":["S1041610224044326"],"URL":"https:\/\/doi.org\/10.1017\/s1041610203008664","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ABC of Alzheimer\u2019s Disease: Cognitive Changes and Their Management in Alzheimer\u2019s Disease and Related Dementias","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610203008664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 International Psychogeriatric Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}